Video
Author(s):
Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses advancements in the management of immune-related adverse events (irAEs) in patients with lung cancer during the 5th Annual Miami Lung Cancer Conference.
Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses advancements in the management of immune-related adverse events (irAEs) in patients with lung cancer during the 5th Annual Miami Lung Cancer Conference.
In the past few years, there have been several guidelines published to assist physicians with diagnosing and identifying immune-related side effects. Pneumonitis is the most common irAE seen in patients with lung cancer, Naidoo says, and it can be difficult to discern the difference between pneumonitis and pneumonia or progression of lung cancer.
It is widely accepted practice now that patients receive a high-resolution CT scan, but they can have a chest xray to start. Patients who are symptomatic should be considered for a bronchoscopy with or without a lung biopsy in order to tell if a patient has pneumonitis.
Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL
Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment
Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer
Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC
2 Commerce Drive
Cranbury, NJ 08512